In a significant move bridging the worlds of artificial intelligence and life sciences, Anthropic has appointed Vas Narasimhan, Chief Executive Officer of Swiss pharmaceutical giant Novartis, to its board of directors. Narasimhan is the first healthcare executive to join the AI startup's board of directors, marking a major milestone for the company.
As developer of the Claude AI models, Anthropic is increasingly positioning itself as a key player in specialised industrial applications. Vas Narasimhan's appointment signals Anthropic's growing focus on the intersection of generative AI and drug discovery.
The Novartis CEO is of the opinion that AI is the need of the hour for advanced medicine. “Working across medicine, innovation, and global health has helped me realise that technology creates the most value when it is deployed responsibly. That's why I'm excited to be joining the Board of Anthropic,” he wrote in a LinkedIn post:
Early Years
Narasimhan graduated in science from world-renowned institutions, earning a degree in biological sciences from the University of Chicago followed by an MD from Harvard. According to The Economic Times, he also completed a Master's in Public Policy at the Harvard Kennedy School, effectively straddling the diverse fields of science, medicine, and policy.
Career
Narasimhan, who has led Novartis since 2018, brings a wealth of experience in navigating complex global regulations and managing the ethical considerations of high-stakes technology. Early in his career, Vasant Narasimhan focused on the front lines of global health, spearheading HIV/AIDS, malaria, and tuberculosis programmes across India, Africa, and South America. This foundational work continues to drive his advocacy for global health equity and expanded access to medicine.
Achievements
Beyond his executive leadership, Narasimhan is a recognised authority in the medical and policy world. He is an elected member of the US National Academy of Medicine and a member of the Council on Foreign Relations. He serves on the University of Chicago's board of trustees and the Harvard Medical School board of fellows. A former chair of the Pharmaceutical Research and Manufacturers of America (PhRMA), he remains an active member of its board of directors.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.